COVID-19 Booster Reduced Hospitalizations, Mortality Risks
Booster vaccines reduced the risk of COVID‑19-related hospitalization and death, according to a new study of over 3 million UK adults who had the autumn 2022 vaccine.
Tag: Pfizer vaccine COVID
All
Latest
COVID-19 Booster Reduced Hospitalizations, Mortality Risks
Booster vaccines reduced the risk of COVID‑19-related hospitalization and death, according to a new study of over 3 million UK adults who had the autumn 2022 vaccine.
Read MorePositive Topline Data for Comirmaty LP.8.1 COVID-19 Vaccine
Preliminary data show the Comirnaty COVID-19 vaccine increases neutralizing antibodies targeting the LP.8.1 sublineage of SARS-CoV-2.
Read MoreFDA Approves Comirnaty COVID-19 Vaccine
The FDA approved Pfizer/BioNTech’s Comirnaty LP.8.1 COVID-19 vaccine for adults age 65+ and those age 5-64 years old with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
Read MorePositive CHMP Opinion for Comirnaty LP.8.1-adapted COVID-19 Vaccine
The European Medicines Agency’s CHMP recommended marketing authorization for the Pfizer/BioNTech’s LP.8.1-adapted monovalent COVID-19 vaccine (Comirnaty LP.8.1).
Read More
FDA Mandates Updated Warning Labels for mRNA COVID-19 Vaccines
The FDA now requires certain COVID-19 vaccines to include safety information about the risks of myocarditis and pericarditis following administration.
Read More
FDA OKs Updated Moderna and Pfizer-BioNTech COVID-19 Vaccines
The FDA has approved and authorized updated Moderna and Pfizer-BioNTech COVID-19 vaccines for the 2024-2025 season, designed to target current variants.
Read More
FDA Includes Myocarditis, Pericaditis Risks for Pfizer and Moderna Vaccines
The FDA has reported increased risks of myocarditis and pericarditis following vaccination with the Moderna and Pfizer-BioNTech COVID-19 vaccine.
Read More